[1]
|
European Diabetes Policy Group, “A Desktop Guide to Type 2 Diabetes Mellitus,” Diabetic Medicine, Vol. 16, No. 9, 1999, pp. 715-730.
|
[2]
|
J. S. Burgers, J. V. Bailey, N. S. Klazinga, et al., “Inside Guidelines: Comparative Analysis of Recommendations and Evidence in Diabetes Guidelines from 13 Countries,” Diabetes Care, Vol. 25, No. 11, 2002, pp. 1933-1939.
doi:10.2337/diacare.25.11.1933
|
[3]
|
S. Bolen, L. Feldman, J. Vassy, et al., “Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus,” Annals of Internal Medicine, Vol. 147, No. 6, 2007, pp. 386-399.
doi:10.7326/0003-4819-147-6-200709180-00178
|
[4]
|
R. Khurana and I. S. Malik, “Metformin: Safety in Cardiac Patients,” Heart, Vol. 96, No. 2, 2010, pp. 99-102.
|
[5]
|
C. A. Naranjo, U. Busto, E. M. Sellers, et al., “A Method for Estimating the Probability of Adverse Drug Reactions,” Clinical Pharmacology & Therapeutics, Vol. 30, No. 2, 1981, pp. 239-245. doi:10.1038/clpt.1981.154
|